TY - JOUR
T1 - Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV
AU - Douglas, Pamela S.
AU - McCallum, Sara
AU - Lu, Michael T.
AU - Umbleja, Triin
AU - Fitch, Kathleen V.
AU - Foldyna, Borek
AU - Zanni, Markella V.
AU - Fulda, Evelynne S.
AU - Bloomfield, Gerald S.
AU - Fichtenbaum, Carl J.
AU - Overton, Edgar T.
AU - Aberg, Judith A.
AU - Malvestutto, Carlos D.
AU - Burdo, Tricia H.
AU - Arduino, Roberto C.
AU - Ho, Ken S.
AU - Yin, Michael T.
AU - Ribaudo, Heather J.
AU - Grinspoon, Steven K.
N1 - Publisher Copyright:
© Copyright 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Objective:To investigate relationships between Life's Simple 7 (LS7), an assessment of cardiovascular health (CVH), and coronary plaque among people with HIV (PWH).Design:Cross-sectional.Methods:Coronary computed tomography angiography, immune/inflammatory biomarkers, and characterization of LS7 were collected among a subset of ART-treated PWH enrolled in REPRIEVE, a primary prevention trial. Analyses adjusted for cardiovascular disease risk (ASCVD score).Results:Median age of the 735 participants was 51(±6) years, 16% female, and median (Q1-Q3) CVD risk was 4.5% (2.6-6.9). Forty percent had poor (≤2 ideal components), 51% had intermediate (three or four ideal components), and only 9% had ideal CVH (≥5). Coronary plaque was present in 357 (49%); 167 (23%) had one or more vulnerable plaque features, 293 (40%) had noncalcified plaque, and 242 (35%) had a coronary artery calcium score >0. All three phenotypes were increasingly more prevalent with poorer CVH and these relationships remained after adjusting for ASCVD risk. Poor CVH was associated with higher high-sensitivity C-reactive protein, oxidized low-density cholesterol, and interleukin-6. The relationship of LS7 to plaque remained after adjusting for these biomarkers.Conclusions:Among PWH, poor CVH as measured by LS7 was associated with coronary plaque presence, vulnerable features, and calcification. LS7 was also associated with selected biomarkers; adjustment for these and ASCVD score reduced but did not eliminate LS7's association with plaque, suggesting the possibility of additional protective mechanisms against atherogenesis and plaque remodeling. Clinical use of LS7 and further exploration of its relationships with coronary artery disease may enhance efforts to reduce cardiovascular morbidity and mortality in PWH.Clinical Trials Registration:NCT02344290.
AB - Objective:To investigate relationships between Life's Simple 7 (LS7), an assessment of cardiovascular health (CVH), and coronary plaque among people with HIV (PWH).Design:Cross-sectional.Methods:Coronary computed tomography angiography, immune/inflammatory biomarkers, and characterization of LS7 were collected among a subset of ART-treated PWH enrolled in REPRIEVE, a primary prevention trial. Analyses adjusted for cardiovascular disease risk (ASCVD score).Results:Median age of the 735 participants was 51(±6) years, 16% female, and median (Q1-Q3) CVD risk was 4.5% (2.6-6.9). Forty percent had poor (≤2 ideal components), 51% had intermediate (three or four ideal components), and only 9% had ideal CVH (≥5). Coronary plaque was present in 357 (49%); 167 (23%) had one or more vulnerable plaque features, 293 (40%) had noncalcified plaque, and 242 (35%) had a coronary artery calcium score >0. All three phenotypes were increasingly more prevalent with poorer CVH and these relationships remained after adjusting for ASCVD risk. Poor CVH was associated with higher high-sensitivity C-reactive protein, oxidized low-density cholesterol, and interleukin-6. The relationship of LS7 to plaque remained after adjusting for these biomarkers.Conclusions:Among PWH, poor CVH as measured by LS7 was associated with coronary plaque presence, vulnerable features, and calcification. LS7 was also associated with selected biomarkers; adjustment for these and ASCVD score reduced but did not eliminate LS7's association with plaque, suggesting the possibility of additional protective mechanisms against atherogenesis and plaque remodeling. Clinical use of LS7 and further exploration of its relationships with coronary artery disease may enhance efforts to reduce cardiovascular morbidity and mortality in PWH.Clinical Trials Registration:NCT02344290.
KW - HIV
KW - atherosclerosis
KW - biomarkers
KW - cardiovascular disease
KW - coronary artery disease
UR - http://www.scopus.com/inward/record.url?scp=85147047818&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000003418
DO - 10.1097/QAD.0000000000003418
M3 - Article
C2 - 36525544
AN - SCOPUS:85147047818
SN - 0269-9370
VL - 37
SP - 423
EP - 434
JO - AIDS
JF - AIDS
IS - 3
ER -